Coxsackievirus (CV) Antigens & Antibodies

Detect and neutralize Coxsackievirus A serotypes associated with hand-foot-and-mouth disease (HFMD) — a common childhood infection that can cause severe neurological complications. Our reagents target VP1 capsid protein of CVA6, CVA10, and CVA16 with recombinant antibodies validated for neutralization, blocking, and SPR, matched polyclonal antibodies for WB and IHC, and His-tagged recombinant VP1 proteins for immunoassay development. RUO

CVA16 Neutralizing AntibodiesThree recombinant clones targeting CVA16 capsid/VP1 with validated neutralization activity: anti-capsid polyprotein (SAA0354-series), anti-mature virion VP1/2/3 (clone 9D7), and anti-VP1 (clone 18A7). Validated for ELISA and neutralization — suitable for vaccine potency assessment and seroconversion studies.

CVA6 Blocking AntibodyRecombinant clone SAA0354 targeting CVA6 VP1 with validated blocking activity, ELISA, and SPR binding data. Suitable for competitive ELISA development and receptor-binding inhibition studies for this increasingly prevalent HFMD serotype.

CVA10 & CVA16 VP1 Proteins & DetectionHis-tagged VP1 recombinant proteins for CVA10 and CVA16, validated for SDS-PAGE, WB, ELISA, and as immunogens. Anti-CVA10 VP1 polyclonal antibody validated for ELISA, WB, and IHC — enabling tissue-based detection in HFMD pathogenesis research.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems.

References

1. Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37(3):391-398. DOI

2. Zhu P, Ji W, Li D, et al. Current status of hand-foot-and-mouth disease. J Biomed Sci. 2023;30(1):15. DOI